{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"164"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"363"}],"units":"Participants"}],"description":"Extended disease free survival will be defined as percentage of patients surviving more than 36 months without relapse or disease progression.","groups":[{"description":"Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m\\^2). Post-transplant maintenance therapy is then prescribed if appropriate.","id":"OG000","title":"Chemotherapy and Transplant Treatment"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"36 Months","title":"Number of Patients With Extended Disease-free Survival","type":"SECONDARY","unitOfMeasure":"Participants"}